Heron Therapeutics, INC. /De/ (HRTX) — 8-K Filings

8-K Filings (18)

• Heron Therapeutics Files 8-K: Officer Changes & Exhibits — Apr 6, 2026 Risk: low
  Heron Therapeutics, Inc. filed an 8-K on April 6, 2026, reporting on the departure of a director and the appointment of a new officer. The filing also includes
• Heron Therapeutics Announces Executive & Director Compensation Changes — Oct 29, 2025 Risk: medium
  Heron Therapeutics, Inc. announced on October 27, 2025, changes in its executive and director compensation arrangements. The filing details the election of new
• Heron Therapeutics Files 8-K on Shareholder Votes & Financials — Oct 15, 2025 Risk: low
  Heron Therapeutics, Inc. filed an 8-K on October 15, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, f
• Heron Therapeutics Files 8-K for Material Agreement — Aug 28, 2025 Risk: medium
  Heron Therapeutics, Inc. (HRTX) filed an 8-K on August 28, 2025, reporting a material definitive agreement entered into on August 22, 2025. The filing also incl
• Heron Therapeutics Enters Material Agreement — Aug 15, 2025 Risk: medium
  Heron Therapeutics, Inc. announced on August 13, 2025, that it entered into a material definitive agreement. The company also reported on material modifications
• Heron Therapeutics Enters Material Definitive Agreement — Aug 12, 2025 Risk: medium
  Heron Therapeutics, Inc. (HRTX) announced on August 6, 2025, that it has entered into a material definitive agreement. The filing does not disclose the specific
• Heron Therapeutics Sets 2025 Annual Meeting Date — Jun 18, 2025 Risk: low
  Heron Therapeutics, Inc. (HRTX) announced on June 12, 2025, that it will hold its 2025 Annual Meeting of Stockholders on July 24, 2025. The meeting will include
• Heron Therapeutics Announces Board and Executive Compensation Changes — Apr 29, 2025 Risk: low
  Heron Therapeutics, Inc. announced on April 28, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elect
• Heron Therapeutics Enters Material Definitive Agreement — Feb 20, 2025 Risk: medium
  Heron Therapeutics, Inc. (HRTX) announced on February 13, 2025, that it entered into a material definitive agreement. The company, formerly known as AP Pharma I
• Heron Therapeutics Files 8-K — Dec 23, 2024 Risk: low
  On December 23, 2024, Heron Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits
• Gilead to Acquire Heron Therapeutics for $1.2 Billion — Dec 3, 2024 Risk: medium
  Heron Therapeutics, Inc. announced on December 3, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for $18.00 per s
• Heron Therapeutics Appoints New Chief Medical Officer — Nov 4, 2024 Risk: medium
  Heron Therapeutics, Inc. announced on November 4, 2024, the appointment of Dr. Michael R. Green as Chief Medical Officer. Dr. Green, who previously served as Se
• Heron Therapeutics Files 8-K Report — Jul 2, 2024 Risk: low
  On July 2, 2024, Heron Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No spe
• Heron Therapeutics Announces Corporate Changes — Jun 18, 2024 Risk: medium
  Heron Therapeutics, Inc. announced on June 13, 2024, a series of significant corporate actions. These include the election of new directors, changes in executiv
• Heron Therapeutics Files 8-K — May 29, 2024 Risk: low
  Heron Therapeutics, Inc. filed an 8-K on May 29, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s
• Heron Therapeutics Announces Board and Executive Compensation Changes — Mar 21, 2024 Risk: low
  Heron Therapeutics, Inc. announced on March 18, 2024, changes in its board of directors and executive compensation. Specifically, Dr. David P. Ryan was appointe
• Heron Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — Jan 24, 2024
  Heron Therapeutics, Inc. (HRTX) filed an 8-K on January 24, 2024, reporting an event that occurred on January 23, 2024. This filing primarily serves to update a
• Heron Therapeutics Reports Undisclosed Material Definitive Agreement — Jan 11, 2024
  Heron Therapeutics, Inc. filed an 8-K on January 11, 2024, to report an "Entry into a Material Definitive Agreement" that occurred on January 5, 2024. While the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX